HilleVax, Inc. (NASDAQ:HLVX) Receives $3.00 Average Price Target from Analysts

Shares of HilleVax, Inc. (NASDAQ:HLVX - Get Free Report) have been given an average recommendation of "Hold" by the six analysts that are presently covering the stock, Marketbeat Ratings reports. Six analysts have rated the stock with a hold recommendation. The average 1 year target price among brokers that have updated their coverage on the stock in the last year is $3.00.

Separately, HC Wainwright restated a "neutral" rating and issued a $2.00 price objective on shares of HilleVax in a report on Monday, March 31st.

HilleVax Stock Performance

HLVX remained flat at $1.86 during trading hours on Tuesday. The company had a trading volume of 116,608 shares, compared to its average volume of 450,960. The stock has a market cap of $93.26 million, a PE ratio of -0.60 and a beta of 0.78. HilleVax has a 12-month low of $1.34 and a 12-month high of $15.60. The business has a fifty day moving average of $1.74 and a 200-day moving average of $1.84.

HilleVax (NASDAQ:HLVX - Get Free Report) last posted its earnings results on Thursday, May 8th. The company reported ($0.12) EPS for the quarter, beating analysts' consensus estimates of ($0.37) by $0.25. As a group, sell-side analysts anticipate that HilleVax will post -2.64 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the company. SG Americas Securities LLC grew its stake in shares of HilleVax by 61.6% in the fourth quarter. SG Americas Securities LLC now owns 18,145 shares of the company's stock valued at $38,000 after buying an additional 6,916 shares in the last quarter. Barclays PLC boosted its holdings in HilleVax by 255.6% during the 3rd quarter. Barclays PLC now owns 42,033 shares of the company's stock valued at $74,000 after acquiring an additional 30,213 shares during the period. Takeda Pharmaceutical Co. Ltd. acquired a new position in HilleVax in the 4th quarter valued at about $13,919,000. Bank of Montreal Can grew its position in HilleVax by 47.1% in the 4th quarter. Bank of Montreal Can now owns 35,763 shares of the company's stock valued at $74,000 after acquiring an additional 11,459 shares in the last quarter. Finally, Intech Investment Management LLC purchased a new stake in HilleVax during the fourth quarter worth about $26,000. 86.42% of the stock is currently owned by institutional investors and hedge funds.

HilleVax Company Profile

HilleVax, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. It develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company was formerly known as MokshaCo, Inc and changed its name to HilleVax, Inc in February 2021.